Security key
008064206
Jade Biosciences, Inc. - Common Stock, $0.0001 par value (JBIO)
CUSIP: 008064206
Q2 2026 13F Holders as of 30 Jun 2026
- Security type / class
- Equity / Common Stock, $0.0001 par value
- Total 13F shares
- 72,902,662
- Total 13F value
- $1,619,316,139
- Share change
- +19,717,724
- Put/Call ratio
- 190%
- SEC-reported price per share
- $22.22
- Number of holders
- 151
- Value change
- +$459,524,266
- Number of buys
- 110
- Number of sells
- 41
- Shares outstanding
- 61,991,928
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2026
Institutions
151
Top holders
10
JBIO full security history
Ownership snapshot
Full 13F holder table
Jade Biosciences, Inc. SEC filings
Jade Biosciences, Inc. company facts
Broader feeds
Ownership snapshot
Top reported holders of JBIO - Jade Biosciences, Inc. - Common Stock, $0.0001 par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Fairmount Funds Managemen...
Disclosed value leader
Fairmount Funds Managemen...
Comparable rows
15/15
Latest evidence
30 Jun 2026
13D/G
3/4/5
13F
Lead comparable stake: 20%
13D/G row: Fairmount Funds Management LLC
Showing 1-6 of 15 holder rows.
Quick read
Fairmount Funds Management LLC leads the comparable SEC ownership view at 20%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Fairmount Funds Management LLC's linked filing trail.
Comparable ownership
Top 5
Fairmount Funds Management LLC
20%
FMR LLC
15%
Janus Henderson Group Ltd.
11%
Venrock Healthcare Capital Partne...
8.3%
RA CAPITAL MANAGEMENT, L.P.
7%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Fairmount Funds Management LLC |
13D/G
3/4/5
13F
Director, 10%+ Owner · Company
|
20%
|
$354,973,334
14,069,494 shares
|
+$93,745,067 | 05 Jun 2026 |
| FMR LLC |
13F
13D/G
Company
|
15%
from 13D/G
|
$99,550,194
7,085,423 shares
|
— | 31 Mar 2026 |
| Janus Henderson Group Ltd. |
13D/G
13F
Company
|
11%
|
$139,393,136
6,273,262 shares
|
+$70,384,550 | 30 Jun 2026 |
| Venrock Healthcare Capital Partners III, L.P. |
13D/G
|
8.3%
|
$107,794,664
5,145,330 shares
|
+$617,355 | 30 Jun 2026 |
| RA CAPITAL MANAGEMENT, L.P. |
13F
13D/G
3/4/5
Company · 10%+ Owner
|
7%
from 13D/G
|
$51,578,716
3,671,083 shares
|
— | 31 Mar 2026 |
| Bellevue Group AG |
13D/G
13F
Company
|
5%
|
$64,065,016
3,057,996 shares
|
-$5,931,092 | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
151
Shares
72,902,662
Rows available
151
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2026 vs Q1 2026 Across Filers
Q1 2026 holders
118
Q2 2026 holders
151
Holder diff
33
| Investor | Q1 2026 Shares | Q2 2026 Shares | Share Diff | Share Chg % | Q1 2026 value | Q2 2026 value | Value change | Value Chg % |
|---|